Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

The eukaryotic translation initiation factor 4E (eIF4E) is a potent oncogene that is found to be dysregulated in 30% of human cancer, including colorectal carcinogenesis (CRC). ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the eIF4E protein....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Duffy, A.G., Makarova-Rusher, O.V., Ulahannan, S.V., Rahma, O.E., Fioravanti, S., Walker, M., Abdullah, S., Raffeld, M., Anderson, V., Abi-Jaoudeh, N., Levy, E., Wood, B.J., Lee, S., Tomita, Y., Trepel, J.B., Steinberg, S.M., Revenko, A.S., MacLeod, A.R., Peer, C.J., Figg, W.D., Greten, T.F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407898/
https://ncbi.nlm.nih.gov/pubmed/27194579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30199
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados